Frazier Healthcare Partners
Venture capital · Seattle, Washington, United States
Portfolio collected from the firm’s website, last checked Jul 26, 2026.Raises and exits come from each company’s own SEC and company records.
17Deep-tech portfolio8 active
9Portfolio exitsAcquired or listed
1Raises, 12 monthsLatest: AirNexis Therapeutics
76Co-investorsShare a portfolio company
Portfolio · 17 companies
| Company | Sector | Status | Latest raise | Raised |
|---|---|---|---|---|
| AirNexis Therapeutics | Biotech | Active | Mar 9, 2026 | $62.0M |
| Enlaza Therapeutics | Biotech | Active | Sep 11, 2025 | $103.0M |
| CinCor Pharma | Biotech | Active | Oct 12, 2021 | $142.9M |
| Prelude Therapeutics | Biotech | Active | Aug 28, 2020 | $97.0M |
| Aspen Neuroscience | Biotech | Active | — | — |
| Mendra | Biotech | Active | — | — |
| Parabilis Medicines | Biotech | Active | — | — |
| Sidewinder Therapeutics | Biotech | Active | — | — |
| Rallybio | Biotech | Public | Apr 22, 2024 | $105.8M |
| Vividion Therapeutics | Biotech | Acquired | Mar 2, 2021 | $240.7M |
| Imago BioSciences | Biotech | Acquired | Nov 20, 2020 | $105.8M |
| Passage Bio | Biotech | Public | Sep 6, 2019 | $110.0M |
| Attovia Therapeutics | Biotech | Public | — | — |
| Braveheart Bio | Biotech | Public | — | — |
| Day One Biopharmaceuticals | Biotech | Acquired | — | — |
| Tubulis | Biotech | Acquired | — | — |
| Turning Point Therapeutics | Biotech | Acquired | — | — |
Peer ranks
Portfolio size#23
Portfolio exits#13
Raises, 12 months#22
Co-investors#5
Co-investors
- Boxer CapitalVenture capital5 shared
- Cormorant Asset ManagementVenture capital4 shared
- EcoR1 CapitalVenture capital4 shared
- OrbiMedVenture capital4 shared
- Perceptive AdvisorsVenture capital4 shared
- Biotechnology Value FundVenture capital3 shared
- Brookside CapitalVenture capital3 shared
- Goldman Sachs AlternativesVenture capital3 shared
- Gurnet Point CapitalVenture capital3 shared
- Perceptive Life SciencesVenture capital3 shared
Sectors
- Biotech17
Portfolios are collected from investors’ own websites and matched to tracked deep-tech companies by name; duplicate listings of the same firm are merged. Exits and raises come from each company’s own record: Form D through the latest filing.